A detailed history of Bnp Paribas transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Bnp Paribas holds 866 shares of REGN stock, worth $600,571. This represents 0.01% of its overall portfolio holdings.

Number of Shares
866
Previous 645 34.26%
Holding current value
$600,571
Previous $338,000 43.79%
% of portfolio
0.01%
Previous 0.01%

Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 14, 2025

BUY
$534.91 - $598.71 $118,215 - $132,314
221 Added 34.26%
866 $486,000
Q2 2025

Aug 14, 2025

SELL
$483.07 - $625.6 $527,995 - $683,780
-1,093 Reduced 62.89%
645 $338,000
Q1 2025

May 14, 2025

BUY
$634.14 - $744.83 $38,048 - $44,689
60 Added 3.58%
1,738 $1.1 Million
Q4 2024

Feb 14, 2025

SELL
$701.85 - $1046.91 $38,601 - $57,580
-55 Reduced 3.17%
1,678 $1.2 Million
Q3 2024

Nov 13, 2024

BUY
$1024.09 - $1201.76 $248,853 - $292,027
243 Added 16.31%
1,733 $1.82 Billion
Q2 2024

Aug 13, 2024

SELL
$883.2 - $1071.19 $261,427 - $317,072
-296 Reduced 16.57%
1,490 $1.57 Billion
Q1 2024

May 01, 2024

BUY
$902.69 - $993.35 $1.61 Million - $1.77 Million
1,786 New
1,786 $1.72 Billion

Others Institutions Holding REGN

About REGENERON PHARMACEUTICALS, INC.


  • Ticker REGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 107,190,000
  • Market Cap $74.3B
  • Description
  • Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...
More about REGN
Track This Portfolio

Track Bnp Paribas Portfolio

Follow Bnp Paribas and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bnp Paribas, based on Form 13F filings with the SEC.

News

Stay updated on Bnp Paribas with notifications on news.